Results 21 to 30 of about 3,092 (212)

Development of antitoxin with each of two complementary fragments of Clostridium botulinum type B derivative toxin [PDF]

Infection and Immunity, 1977
Two fragments with molecular weights of 111,000 (fragment I) and 59,000 (fragment II) were separated from each other by gel filtration of dithiothreitol and urea-treated, trypsinized derivative toxin (molecular weight, 170,000) of the proteolytic Okra strain of Clostridium botulinum type B on a column of Sephadex G-200 (superfine) with a buffer ...
S Kozaki, S Miyazaki, G Sakaguchi
openaire   +4 more sources

Antitoxins and botulinum toxin treatment. [PDF]

BMJ, 1992
J. Melling, P. Hambleton, H. E. Cohen, B. J. Palmer   +3 more
openaire   +4 more sources

Algal chloroplast produced camelid V_HH antitoxins are capable of neutralizing botulinum neurotoxin [PDF]

Plant Biotechnology Journal, 2014
SummaryWe have produced three antitoxins consisting of the variable domains of camelid heavy chain‐only antibodies (VHH) by expressing the genes in the chloroplast of green algae. These antitoxins accumulate as soluble proteins capable of binding and neutralizing botulinum neurotoxin.
Barrera, Daniel J, Rosenberg, Julian N, Chiu, Joanna G, Chang, Yung‐Nien, Debatis, Michelle, Ngoi, Soo‐Mun, Chang, John T, Shoemaker, Charles B, Oyler, George A, Mayfield, Stephen P   +9 more
openaire   +6 more sources

Standardization of the Japanese National Standard, Equine Botulinum Antitoxin Type A, and Factors Affecting Standardization

Japanese Journal of Infectious Diseases, 2023
Equine botulinum antitoxin is one of the most popular countermeasures for human botulism. The unitage of the antitoxin product is defined according to national minimum requirement or pharmacopoeia in each country by referring to national standard antitoxins for four types (A, B, E, and F). With the expected depletion of the national standard antitoxins,
Masahiro, Yutani, Mitsutoshi, Senoh, Hiroko, Yano, Tsuyoshi, Kenri, Masaaki, Iwaki   +4 more
openaire   +4 more sources

Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs.

PLoS ONE, 2019
Botulism neurotoxins are highly toxic and are potential agents for bioterrorism. The development of effective therapy is essential to counter the possible use of these toxins in military and bioterrorism scenarios, and to provide treatment in cases of ...
Douglas Barker, Karen T Gillum, Nancy A Niemuth, Shantha Kodihalli   +3 more
doaj   +3 more sources

Characterization of Botulinum Neurotoxin Type A Neutralizing Monoclonal Antibodies and Influence of Their Half-Lives on Therapeutic Activity [PDF]

PLoS ONE, 2010
Botulinum toxins, i.e. BoNT/A to/G, include the most toxic substances known. Since botulism is a potentially fatal neuroparalytic disease with possible use as a biowarfare weapon (Centers for Disease Control and Prevention category A bioterrorism agent),
A Nowakowski, AP Chapman, AP Chapman, AT Carter, CC Shone, Christelle Mazuet, Christophe Créminon, CL Hatheway, CN Mayers, DD Pless, DR Franz, E Lamoyi, ED Lobo, H Volland, HC Wu, Hervé Volland, Holger Bruggemann, IL Koumenis, Julie Dano, JW Arndt, KK Hill, LA Broussard, LA Smith, M Tavallaie, MA Clayton, Michel R. Popoff, MJ Knauf, MW Wheeler, N Dover, P Amersdorfer, RE Black, RE Sheridan, RGA Jones, SK Batra, SR Leong, SS Arnon, TJ Smith, TW Smith, W Liu, Y Torii   +39 more
core   +12 more sources

Recombinant expression of receptor binding domains of all eight subtypes of botulinum neurotoxin type A for generation of antitoxins with broad reactivity. [PDF]

F1000Res
Quynh Pham N, Mai TT, Dang TBA, Huong Tran L, Mai Vu Q, Trong Nguyen C, Thi Phuong Tran A, Dang TNM, Tran VA, Huy Tran T, Tran VK, Quang Le H.   +11 more
europepmc   +2 more sources

Diagnosis and treatment of botulism after botulinum toxin type A injections: report of 9 cases

Di-san junyi daxue xuebao, 2021
Objective To explore the diagnostic criteria of botulism after botulinum toxin type A (BT/A) injection and observe the therapeutic effect of botulinum antitoxin.
HE Ping, ZHANG Jianghe, YAN Rongshuai, FAN Dongli, WANG Shaoliang, MAO Tongchun   +5 more
doaj   +1 more source

A Rabbit Model for the Evaluation of Drugs for Treating the Chronic Phase of Botulism

Toxins, 2021
Antitoxin, the only licensed drug therapy for botulism, neutralizes circulating botulinum neurotoxin (BoNT). However, antitoxin is no longer effective when a critical amount of BoNT has already entered its target nerve cells.
Amram Torgeman, Eran Diamant, Eyal Dor, Arieh Schwartz, Tzadok Baruchi, Alon Ben David, Ran Zichel   +6 more
doaj   +1 more source

A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice

Toxins, 2023
Equine-derived antitoxin (BAT®) is the only treatment for botulism from botulinum neurotoxin serotype G (BoNT/G). BAT® is a foreign protein with potentially severe adverse effects and is not renewable.
Yongfeng Fan, Jianlong Lou, Christina C. Tam, Weihua Wen, Fraser Conrad, Priscila Leal da Silva Alves, Luisa W. Cheng, Consuelo Garcia-Rodriguez, Shauna Farr-Jones, James D. Marks   +9 more
doaj   +1 more source